PAVmed (NASDAQ:PAVM) Given New $20.00 Price Target at Ascendiant Capital Markets

PAVmed (NASDAQ:PAVM) had its price objective hoisted by Ascendiant Capital Markets from $19.00 to $20.00 in a report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of PAVmed in a report on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.00.

PAVmed Price Performance

Shares of NASDAQ:PAVM opened at $0.45 on Monday. PAVmed has a 12 month low of $0.30 and a 12 month high of $1.29. The stock has a market cap of $9.86 million, a price-to-earnings ratio of 0.39 and a beta of 1.07. The stock’s 50 day moving average price is $0.46 and its 200 day moving average price is $0.59.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC grew its position in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. 19.93% of the stock is owned by hedge funds and other institutional investors.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.